ClinicaliQ Trial Snapshot
- METEL Study Which is to Collect Urine Samples From Patients to Analyse Their Chemistry to Assess How Close to Death the Patient is at Point of Sample When They Have a Solid Cancer Tumour Diagnosis — Recruiting • Oncology • NCT07848997.
- What is being tested: The METEL study analyzes urine chemistry in patients with solid cancer tumors to develop biomarkers that indicate proximity to death, enabling assessment of disease progression and prognosis at the time of sampling.
- Patient eligibility overview: The study recruits patients with confirmed solid cancer tumor diagnoses who provide urine samples for chemical analysis; specific inclusion/exclusion criteria would determine which cancer types and disease stages are enrolled.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Use of samples from patients with solid cancer tumour diagnosis to assess chemistry
Eligibility Snapshot
- : * Must have as solid cancer tumour diagnosis Must be over the age of 18 Must be able to understand and communicate in English Must be able to provide fully informed consent at the point of trial entry Must be able to urinate freely or be catheterised
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.